Fecal microbiota transplantation: a review on current formulations in Clostridioides difficile infection and future outlooks.
Details
Serval ID
serval:BIB_6C90CE45CFC9
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Fecal microbiota transplantation: a review on current formulations in Clostridioides difficile infection and future outlooks.
Journal
Expert opinion on biological therapy
ISSN
1744-7682 (Electronic)
ISSN-L
1471-2598
Publication state
Published
Issued date
07/2022
Peer-reviewed
Oui
Volume
22
Number
7
Pages
929-944
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Publication Status: ppublish
Abstract
The role of the gut microbiota in health and the pathogenesis of several diseases has been highlighted in recent years. Even though the precise mechanisms involving the microbiome in these ailments are still unclear, microbiota-modulating therapies have been developed. Fecal microbiota transplantation (FMT) has shown significant results against Clostridioides difficile infection (CDI), and its potential has been investigated for other diseases. Unfortunately, the technical aspects of the treatment make it difficult to implement. Pharmaceutical technology approaches to encapsulate microorganisms could play an important role in providing this treatment and render the treatment modalities easier to handle.
After an overview of CDI, this narrative review aims to discuss the current formulations for FMT and specifically addresses the technical aspects of the treatment. This review also distinguishes itself by focusing on the hurdles and emphasizing the possible improvements using pharmaceutical technologies.
FMT is an efficient treatment for recurrent CDI. However, its standardization is overlooked. The approach of industrial and hospital preparations of FMT are different, but both show promise in their respective methodologies. Novel FMT formulations could enable further research on dysbiotic diseases in the future.
After an overview of CDI, this narrative review aims to discuss the current formulations for FMT and specifically addresses the technical aspects of the treatment. This review also distinguishes itself by focusing on the hurdles and emphasizing the possible improvements using pharmaceutical technologies.
FMT is an efficient treatment for recurrent CDI. However, its standardization is overlooked. The approach of industrial and hospital preparations of FMT are different, but both show promise in their respective methodologies. Novel FMT formulations could enable further research on dysbiotic diseases in the future.
Keywords
Clostridioides difficile, Clostridium Infections/therapy, Dysbiosis, Fecal Microbiota Transplantation/adverse effects, Fecal Microbiota Transplantation/methods, Gastrointestinal Microbiome, Humans, Recurrence, Treatment Outcome, Bacterial formulation, Clostridioides difficile infection, dysbiosis, fecal microbiota transplantation, live bacteria administration, microbiota, pharmaceutical technology
Pubmed
Web of science
Create date
04/07/2022 12:28
Last modification date
31/01/2023 7:55